Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.34 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.37 +0.03 (1.28%) 5:18 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.34 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.37 +0.03 (1.28%) 5:18 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Zacks News
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
by Zacks Equity Research
InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
by Zacks Equity Research
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review
by Zacks Equity Research
Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
by Zacks Equity Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Wall Street Analysts Think Esperion Therapeutics (ESPR) Could Surge 32%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 32.5% upside potential for Esperion Therapeutics (ESPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has UnitedHealth Group (UNH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how UnitedHealth Group (UNH) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.
Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.90% and 4.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
Esperion Therapeutics (ESPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Esperion Therapeutics (ESPR): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
Esperion Therapeutics (ESPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is United Therapeutics (UTHR) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -10.53% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Esperion Therapeutics (ESPR) Down 15.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?
by Zacks Equity Research
Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.
Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 3.12% and 21.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
by Zacks Equity Research
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion's (ESPR) Drug Sales and Cost-Cutting Drive Stock YTD
by Zacks Equity Research
Esperion's (ESPR) stock rallies so far this year on higher product sales in the fourth quarter of 2021. Cost-saving initiatives to boost margins in 2022 are another key drivers.
Why Is Esperion Therapeutics (ESPR) Up 29.1% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.